McMaster University and Cisco Systems Canada Co. announced they have established a long-term relationship which will see the university increase research activities in Integrated Health Biosystems and Bioinformatics. McMaster and Cisco will also establish a university-wide research cloud computing environment and infrastructure. This partnership will see McMaster build on its renowned research successes and strengthen its links with national and international partners from academia, government and industry. As part of the agreement, Cisco is providing a $2.1 million contribution to McMaster. The contribution includes $1.6 million over eight years to establish a Professorship in Integrated Health Biosystems, as well as $500,000 over five years to establish a Research Chair in Bioinformatics. The Research Chair in Bioinformatics will collaborate on a program in Integrated Health Biosystems, the aim of which will be to bridge the existing gulf between data-intensive areas of biomedical research and healthcare by integrating diverse biological datasets with clinical and environmental data.

Genoa Pharmaceuticals, Inc. announced it is collaborating with Dr. Martin Kolb and researchers at McMaster University to characterize the in vivo advantages and potential clinical impact of Genoa's lead program, inhaled GP-101 (aerosol pirfenidone) for the treatment of IPF. The research will combine Genoa's expertise in aerosol drug delivery with McMaster's expertise in exploring mechanisms of pulmonary fibrosis and managing patients with IPF.

Mcmaster University Presents at Paydirt's 2012 Uranium Conference, Feb-28-2012 through Feb-29-2012. Venue: Hilton Adelaide Hotel, Adelaide, Victoria, Australia. Presentation Date & Speakers: Feb-28-2012, Doug Boreham, Principal Scientist.